Ann: Race Strategic Update August 2023, page-245

Hi@Rossi70
Welcome back. Hope you had a great holiday.
The timelines are there to outline, how long it would take if they take it all the way, themselves.
But they've been clear, they want to partner with multiple entities for different indications, in the near to medium term.
Gauging at investor seminar and some talks, they seem to be eager to sell after Proof of Concept Results.
It's just the share price, that's not so good.
But fundamentally, we are getting better, going after unmet need, that makes sense commercially.
The opportunity is still huge, the drug still works, we just need a bunch of patient investors, who understand the play.
I am happy to wait it out a couple of years, and see what happens, and quite possible we'll be sold off by then, on the back of cardioprotection data alone, as BP would be hard pressed not to put an offer, then. IMO.